Trial Number

697-16

Age range

18 Years to 85 Years

Gender

Male or Female

Enrolling Patients

Yes

The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

Principal Investigator

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
How did you hear about us?
This registration is for:
7 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.